Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
This is a phase 1 clinical trial of SPH3348 tablets, a c-Met inhibitor, in patients with
advanced solid tumors with c-Met abnormalities. A modified 3 + 3 design was adopted in
patients with advanced solid tumors with c-Met abnormalities, with a total of 6 dose groups,
in which accelerated dose escalation was adopted for the lowest dose group, and 3 + 3 dose
escalation was adopted from the second dose group. The primary objective was to evaluate the
safety and tolerability of SPH3348 tablets in patients with advanced solid tumors with c-Met
abnormalities.